Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ADXS-503 |
Trade Name | |
Synonyms | ADXS-HOT|ADXS503|ADXS 503 |
Drug Descriptions |
ADXS-503 is an immunotherapy based on a Listeria monocytogenes strain expressing tumor-specific hotspot antigens, including KRAS G12D, which may result in increased anti-tumor immune response and decreased tumor growth (Cancer Res 2018; 78 (13 Suppl):Abstract nr LB-149). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C158466 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ADXS-503 | ADXS-503 | 0 | 1 |
ADXS-503 + Pembrolizumab | ADXS-503 Pembrolizumab | 0 | 1 |